Trikafta in Cystic Fibrosis Patients

Inclusion Criteria: * Provision of signed and dated informed consent form or assent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female age ≥12 * A clinical diagnosis of CF or CFTR-related disease and either: 1) evidence for a partial function mutation not currently covered or likely to be covered for treatment with a CFTR modulator (Substudy 1), or 2) N1303K CFTR and a minimal function mutation (Substudy 2) * Sweat Chloride \< 80 mmol/L and/or pancreatic sufficiency (no exogenous pancreatic enzyme supplement therapy) or carrying the N1303K CFTR variant * Able to perform spirometry meeting American Thoracic Society (ATS) criteria for acceptability and repeatability * Clinically stable in the past 4 weeks with no evidence of CF exacerbation (prior to screening and study Day 1) * Willingness to use at least one form of acceptable birth control including abstinence or condom with spermicide. This will include birth control for at least one month prior to screening and agreement to use such a method during study participation for an additional four weeks after the last administration of study drug * Ability to take Trikafta * Agreement to adhere to all current medical therapies as designated by the CF care center physician Exclusion Criteria: * Documented history of drug or alcohol abuse within the last year * Subjects should not have a pulmonary exacerbation or changes in therapy for pulmonary disease i…